Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
Ondas Secures $110M in Q2 Orders, Dilution Concerns Persist
Ondas Inc. has secured over $110 million in Q2 orders, driven by defense and autonomous systems demand. However, dilution risks from a higher share count and resale filings continue to pressure the stock.
Amazon Slips Despite $6 Billion AWS Deal with Snowflake; S&P 500 Hits New High
Amazon shares dropped 1.2% to $270.64 even as the S&P 500 reached a new high. A $6 billion AWS deal with Snowflake sent Snowflake shares up 33%, but Amazon's heavy AI spending dragged on free cash flow.
Coherent Stock Slips 6.6% Amid Profit-Taking in AI Optics Sector
Coherent Corp. (COHR) dropped 6.6% to around $352 on Friday, even as the broader market rose, signaling profit-taking in AI optics stocks.
Dow Closes Above 51,000 as Falling Oil and Iran Truce Hopes Lift Sentiment
The Dow Jones Industrial Average closed above 51,000, up 358.82 points, as falling oil prices and hopes for a U.S.-Iran truce boosted market sentiment.
DevvStream Stock Skyrockets 150% on Merger Confirmation
DevvStream shares surged 150% after confirming its three-way merger with XCF Global and Southern Energy Renewables remains active. The company plans an SEC Form S-4 filing soon.
Keel Infrastructure Extends Rally as AI Data Center Aspirations Drive Investor Interest
Keel Infrastructure shares continued their surge Friday, gaining 2.1% to $5.69, as investors focus on the company's transformation into an AI data center provider, even without a signed colocation deal.
NuScale Power Jumps 5% as SMR Licensing Reform and TVA Deal Await
NuScale Power shares gained 5.3% on Friday as investors focused on regulatory reforms and a possible TVA power purchase agreement.
NIO Stock Rises on ES9 Launch Amid China EV Market Challenges
NIO's US-listed shares rose 1.6% to $5.64 after the ES9 flagship SUV launch. Q1 deliveries surged 98% YoY but slipped from Q4, as CEO Li cautions China's auto market has left its 'golden era.'
Replimune Surges 85% on FDA Priority Review for Melanoma Drug
Replimune shares soared 85% after the FDA agreed to a priority review for its melanoma drug RP1, following a previous rejection. New trial data is expected soon.